Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial
Background. Ponatinib is a third-generation tyrosine kinase inhibitor indicated for adults with resistant or intolerant chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia, or those carrying...
Saved in:
Published in | Blood Vol. 138; no. Supplement 1; p. 3603 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
23.11.2021
|
Online Access | Get full text |
Cover
Loading…
Abstract | Background. Ponatinib is a third-generation tyrosine kinase inhibitor indicated for adults with resistant or intolerant chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia, or those carrying the T315I mutation. Ponatinib has been commercially available since January 2015, yet there is a paucity of data on its use in the real-world setting. The goal of the Observational study of Iclusig ® (ponatinib) Treatment in patients with CML in Italy (OITI) was to evaluate treatment patterns and outcomes, including safety and efficacy, in patients with CML treated in Italy since the approval of ponatinib.
Methods. This noninterventional study included patients aged ≥18 years with CP, AP, or BP CML who initiated ponatinib treatment in routine clinical practice across 26 Italian centers (academic and hospital settings). The study population comprised a prospective cohort, including patients who started treatment with ponatinib after site activation during the 12-month enrollment period; a retrospective cohort, including patients who started treatment with ponatinib but died or were lost to follow-up prior to site activation; and a retrospective/prospective cohort, including patients who started treatment with ponatinib prior to site activation and were still on treatment or in follow-up at the end of the study. Demographic, efficacy, and safety data were collected from patient medical charts at study entry and routine visits. The primary endpoint was the complete cytogenetic response (CCyR) rate in CP CML patients 6 months after starting ponatinib. In the absence of cytogenetic evaluation, molecular assessment was used, considering patients in MR2 or better to be in CCyR. Here, the primary analysis of all evaluable patients for the primary endpoint (median follow-up, 23.7 months [range, 1.3-70.8]) is presented.
Results. A total of 119 patients (110 CP, 6 AP, and 3 BP CML) were analyzed. Fifty-nine (49.6%) received ponatinib in second-line (2L), 41 (34.4%) in 3L, and 19 (16.0%) in ≥4L. Prior cardiovascular disease/hypertension was recorded in 56 (47.1%) patients. Median age at ponatinib start was 60 years (range, 19-93). Of 68 evaluated patients, 24 (35.3%) had a confirmed ABL1 mutation, including 7 (10.3%) with the T315I mutation. Starting doses of ponatinib were 45 mg (37.0%), 30 mg (41.2%), or 15 mg (21.8%). Median treatment duration was 22.8 months (range, 1.4-73.6). At baseline, 56 patients with CP CML had less than CCyR and 53 were in CCyR. For 1 patient, assessment was not available.
At 6 months, 80/107 evaluable patients with CP CML were in CCyR; 29/56 (51.8%) achieved and 50/50 (100%) maintained CCyR compared to baseline, respectively. For 1 patient, baseline data were unavailable. Additionally, 37 (34.6%) and 19 (17.8%) patients with CP CML achieved a major molecular response (MMR; MR3) and a deep molecular response (MR4-MR5), respectively (Table 1). Progression-free survival rates estimated for patients with CP CML at 12 and 24 months were 92.6% (95% CI, 87.8-97.7%) and 84.6% (95% CI, 77.2-92.6%), respectively. Corresponding overall survival rates were 95.4% (95% CI, 91.6-99.4%), and 88.4% (95% CI, 81.7-95.7%).
Seventy-one (59.7%) patients had treatment-related adverse events (AEs), most commonly rash, hypertension (Grade 1-2), and thrombocytopenia (Grade 3). Treatment-related arterial occlusive events occurred in 2 (1.7%) patients. Dose modifications occurred in 77 patients: 37.1% were due to AEs, 13.5% were reductions after at least major cytogenetic response, 10.6% were increases due to lack of efficacy, 1.7% were medical decisions, and 37.1% were for other reasons. Thirty-three patients discontinued ponatinib due to AEs (33.3%), medical decisions (24.2%), and other reasons (42.4%), such as death, progression, and hematopoietic stem cell transplantation.
Conclusions. This observational study demonstrates that ponatinib has a favorable efficacy and safety profile in patients with CML treated in standard clinical practice. By 6 months, 74.8% of evaluable patients were in CCyR and 52.3% achieved at least MMR. Further, the probability of survival at 2 years was >88%. No new safety signals emerged with ponatinib treatment compared to prior studies. The early use of ponatinib and careful dose selection appear key to the safety and efficacy outcomes observed in this real-world study.
[Display omitted]
Breccia: Abbvie: Honoraria; Bristol Myers Squibb/Celgene: Honoraria; Incyte: Honoraria; Novartis: Honoraria; Pfizer: Honoraria. Abruzzese: Novartis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Incyte: Consultancy, Honoraria. Bonifacio: Pfizer: Honoraria; Amgen: Honoraria; Bristol Myers Squibb: Honoraria; Novartis: Honoraria. Castagnetti: Novartis: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria. Galimberti: Inctye Bioscience Italy Srl: Current Employment. Iurlo: Incyte: Speakers Bureau; Novartis: Speakers Bureau; Pfizer: Speakers Bureau; Bristol Myers Squibb: Speakers Bureau. |
---|---|
AbstractList | Background. Ponatinib is a third-generation tyrosine kinase inhibitor indicated for adults with resistant or intolerant chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia, or those carrying the T315I mutation. Ponatinib has been commercially available since January 2015, yet there is a paucity of data on its use in the real-world setting. The goal of the Observational study of Iclusig ® (ponatinib) Treatment in patients with CML in Italy (OITI) was to evaluate treatment patterns and outcomes, including safety and efficacy, in patients with CML treated in Italy since the approval of ponatinib.
Methods. This noninterventional study included patients aged ≥18 years with CP, AP, or BP CML who initiated ponatinib treatment in routine clinical practice across 26 Italian centers (academic and hospital settings). The study population comprised a prospective cohort, including patients who started treatment with ponatinib after site activation during the 12-month enrollment period; a retrospective cohort, including patients who started treatment with ponatinib but died or were lost to follow-up prior to site activation; and a retrospective/prospective cohort, including patients who started treatment with ponatinib prior to site activation and were still on treatment or in follow-up at the end of the study. Demographic, efficacy, and safety data were collected from patient medical charts at study entry and routine visits. The primary endpoint was the complete cytogenetic response (CCyR) rate in CP CML patients 6 months after starting ponatinib. In the absence of cytogenetic evaluation, molecular assessment was used, considering patients in MR2 or better to be in CCyR. Here, the primary analysis of all evaluable patients for the primary endpoint (median follow-up, 23.7 months [range, 1.3-70.8]) is presented.
Results. A total of 119 patients (110 CP, 6 AP, and 3 BP CML) were analyzed. Fifty-nine (49.6%) received ponatinib in second-line (2L), 41 (34.4%) in 3L, and 19 (16.0%) in ≥4L. Prior cardiovascular disease/hypertension was recorded in 56 (47.1%) patients. Median age at ponatinib start was 60 years (range, 19-93). Of 68 evaluated patients, 24 (35.3%) had a confirmed ABL1 mutation, including 7 (10.3%) with the T315I mutation. Starting doses of ponatinib were 45 mg (37.0%), 30 mg (41.2%), or 15 mg (21.8%). Median treatment duration was 22.8 months (range, 1.4-73.6). At baseline, 56 patients with CP CML had less than CCyR and 53 were in CCyR. For 1 patient, assessment was not available.
At 6 months, 80/107 evaluable patients with CP CML were in CCyR; 29/56 (51.8%) achieved and 50/50 (100%) maintained CCyR compared to baseline, respectively. For 1 patient, baseline data were unavailable. Additionally, 37 (34.6%) and 19 (17.8%) patients with CP CML achieved a major molecular response (MMR; MR3) and a deep molecular response (MR4-MR5), respectively (Table 1). Progression-free survival rates estimated for patients with CP CML at 12 and 24 months were 92.6% (95% CI, 87.8-97.7%) and 84.6% (95% CI, 77.2-92.6%), respectively. Corresponding overall survival rates were 95.4% (95% CI, 91.6-99.4%), and 88.4% (95% CI, 81.7-95.7%).
Seventy-one (59.7%) patients had treatment-related adverse events (AEs), most commonly rash, hypertension (Grade 1-2), and thrombocytopenia (Grade 3). Treatment-related arterial occlusive events occurred in 2 (1.7%) patients. Dose modifications occurred in 77 patients: 37.1% were due to AEs, 13.5% were reductions after at least major cytogenetic response, 10.6% were increases due to lack of efficacy, 1.7% were medical decisions, and 37.1% were for other reasons. Thirty-three patients discontinued ponatinib due to AEs (33.3%), medical decisions (24.2%), and other reasons (42.4%), such as death, progression, and hematopoietic stem cell transplantation.
Conclusions. This observational study demonstrates that ponatinib has a favorable efficacy and safety profile in patients with CML treated in standard clinical practice. By 6 months, 74.8% of evaluable patients were in CCyR and 52.3% achieved at least MMR. Further, the probability of survival at 2 years was >88%. No new safety signals emerged with ponatinib treatment compared to prior studies. The early use of ponatinib and careful dose selection appear key to the safety and efficacy outcomes observed in this real-world study.
[Display omitted]
Breccia: Abbvie: Honoraria; Bristol Myers Squibb/Celgene: Honoraria; Incyte: Honoraria; Novartis: Honoraria; Pfizer: Honoraria. Abruzzese: Novartis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Incyte: Consultancy, Honoraria. Bonifacio: Pfizer: Honoraria; Amgen: Honoraria; Bristol Myers Squibb: Honoraria; Novartis: Honoraria. Castagnetti: Novartis: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria. Galimberti: Inctye Bioscience Italy Srl: Current Employment. Iurlo: Incyte: Speakers Bureau; Novartis: Speakers Bureau; Pfizer: Speakers Bureau; Bristol Myers Squibb: Speakers Bureau. Abstract Background. Ponatinib is a third-generation tyrosine kinase inhibitor indicated for adults with resistant or intolerant chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia, or those carrying the T315I mutation. Ponatinib has been commercially available since January 2015, yet there is a paucity of data on its use in the real-world setting. The goal of the Observational study of Iclusig ® (ponatinib) Treatment in patients with CML in Italy (OITI) was to evaluate treatment patterns and outcomes, including safety and efficacy, in patients with CML treated in Italy since the approval of ponatinib. Methods. This noninterventional study included patients aged ≥18 years with CP, AP, or BP CML who initiated ponatinib treatment in routine clinical practice across 26 Italian centers (academic and hospital settings). The study population comprised a prospective cohort, including patients who started treatment with ponatinib after site activation during the 12-month enrollment period; a retrospective cohort, including patients who started treatment with ponatinib but died or were lost to follow-up prior to site activation; and a retrospective/prospective cohort, including patients who started treatment with ponatinib prior to site activation and were still on treatment or in follow-up at the end of the study. Demographic, efficacy, and safety data were collected from patient medical charts at study entry and routine visits. The primary endpoint was the complete cytogenetic response (CCyR) rate in CP CML patients 6 months after starting ponatinib. In the absence of cytogenetic evaluation, molecular assessment was used, considering patients in MR2 or better to be in CCyR. Here, the primary analysis of all evaluable patients for the primary endpoint (median follow-up, 23.7 months [range, 1.3-70.8]) is presented. Results. A total of 119 patients (110 CP, 6 AP, and 3 BP CML) were analyzed. Fifty-nine (49.6%) received ponatinib in second-line (2L), 41 (34.4%) in 3L, and 19 (16.0%) in ≥4L. Prior cardiovascular disease/hypertension was recorded in 56 (47.1%) patients. Median age at ponatinib start was 60 years (range, 19-93). Of 68 evaluated patients, 24 (35.3%) had a confirmed ABL1 mutation, including 7 (10.3%) with the T315I mutation. Starting doses of ponatinib were 45 mg (37.0%), 30 mg (41.2%), or 15 mg (21.8%). Median treatment duration was 22.8 months (range, 1.4-73.6). At baseline, 56 patients with CP CML had less than CCyR and 53 were in CCyR. For 1 patient, assessment was not available. At 6 months, 80/107 evaluable patients with CP CML were in CCyR; 29/56 (51.8%) achieved and 50/50 (100%) maintained CCyR compared to baseline, respectively. For 1 patient, baseline data were unavailable. Additionally, 37 (34.6%) and 19 (17.8%) patients with CP CML achieved a major molecular response (MMR; MR3) and a deep molecular response (MR4-MR5), respectively (Table 1). Progression-free survival rates estimated for patients with CP CML at 12 and 24 months were 92.6% (95% CI, 87.8-97.7%) and 84.6% (95% CI, 77.2-92.6%), respectively. Corresponding overall survival rates were 95.4% (95% CI, 91.6-99.4%), and 88.4% (95% CI, 81.7-95.7%). Seventy-one (59.7%) patients had treatment-related adverse events (AEs), most commonly rash, hypertension (Grade 1-2), and thrombocytopenia (Grade 3). Treatment-related arterial occlusive events occurred in 2 (1.7%) patients. Dose modifications occurred in 77 patients: 37.1% were due to AEs, 13.5% were reductions after at least major cytogenetic response, 10.6% were increases due to lack of efficacy, 1.7% were medical decisions, and 37.1% were for other reasons. Thirty-three patients discontinued ponatinib due to AEs (33.3%), medical decisions (24.2%), and other reasons (42.4%), such as death, progression, and hematopoietic stem cell transplantation. Conclusions. This observational study demonstrates that ponatinib has a favorable efficacy and safety profile in patients with CML treated in standard clinical practice. By 6 months, 74.8% of evaluable patients were in CCyR and 52.3% achieved at least MMR. Further, the probability of survival at 2 years was >88%. No new safety signals emerged with ponatinib treatment compared to prior studies. The early use of ponatinib and careful dose selection appear key to the safety and efficacy outcomes observed in this real-world study. Figure 1 Figure 1. Disclosures Breccia: Abbvie: Honoraria; Bristol Myers Squibb/Celgene: Honoraria; Incyte: Honoraria; Novartis: Honoraria; Pfizer: Honoraria. Abruzzese: Novartis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Incyte: Consultancy, Honoraria. Bonifacio: Pfizer: Honoraria; Amgen: Honoraria; Bristol Myers Squibb: Honoraria; Novartis: Honoraria. Castagnetti: Novartis: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria. Galimberti: Inctye Bioscience Italy Srl: Current Employment. Iurlo: Incyte: Speakers Bureau; Novartis: Speakers Bureau; Pfizer: Speakers Bureau; Bristol Myers Squibb: Speakers Bureau. |
Author | Scortechini, Anna Rita Lunghi, Monia Attolico, Imma Di Renzo, Nicola Piciocchi, Alfonso Impera, Stefana Abruzzese, Elisabetta Castagnetti, Fausto Sargentini, Valeria Malato, Alessandra Cascavilla, Nicola Maggi, Alessandro Santoro, Marco Galimberti, Claudia Iurlo, Alessandra Bonifacio, Massimiliano Annunziata, Mario Luciano, Luigia Breccia, Massimo |
Author_xml | – sequence: 1 givenname: Massimo surname: Breccia fullname: Breccia, Massimo organization: Division of Hematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University, Rome, Italy – sequence: 2 givenname: Luigia surname: Luciano fullname: Luciano, Luigia organization: Hematology Unit, Federico II University of Naples, Napoli, Italy – sequence: 3 givenname: Mario surname: Annunziata fullname: Annunziata, Mario organization: Hematology Unit, Azienda Ospedaliera Cardarelli, Naples, Italy – sequence: 4 givenname: Imma surname: Attolico fullname: Attolico, Imma organization: Haematology and Transplants Unit, University of Bari, Bari, Italy – sequence: 5 givenname: Alessandra surname: Malato fullname: Malato, Alessandra organization: Department of Hematology, Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy – sequence: 6 givenname: Elisabetta surname: Abruzzese fullname: Abruzzese, Elisabetta organization: Hematology, S. Eugenio Hospital, Tor Vergata University, Rome, Italy – sequence: 7 givenname: Massimiliano surname: Bonifacio fullname: Bonifacio, Massimiliano organization: Department of Medicine, Section of Hematology, University of Verona, Verona, Italy – sequence: 8 givenname: Anna Rita surname: Scortechini fullname: Scortechini, Anna Rita organization: Division of Hematology, Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona, Italy – sequence: 9 givenname: Nicola surname: Cascavilla fullname: Cascavilla, Nicola organization: Division of Hematology, IRCCS Casa Sollievo Della Sofferenza Hospital, San Giovanni Rotondo, Italy – sequence: 10 givenname: Nicola surname: Di Renzo fullname: Di Renzo, Nicola organization: Department of Hematology and Stem Cell Transplant, Presidio Ospedaliero Vito Fazzi, Lecce, Italy – sequence: 11 givenname: Stefana surname: Impera fullname: Impera, Stefana organization: Division of Hematology, ARNAS Garibaldi, Catania, Italy – sequence: 12 givenname: Monia surname: Lunghi fullname: Lunghi, Monia organization: Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy – sequence: 13 givenname: Marco surname: Santoro fullname: Santoro, Marco organization: Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy – sequence: 14 givenname: Fausto surname: Castagnetti fullname: Castagnetti, Fausto organization: Istituto di Ematologia “Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Bologna, Italy – sequence: 15 givenname: Alessandro surname: Maggi fullname: Maggi, Alessandro organization: Division of Hematology, Hospital “S.G. Moscati”, Taranto, Italy – sequence: 16 givenname: Valeria surname: Sargentini fullname: Sargentini, Valeria organization: GIMEMA Foundation, Rome, Italy – sequence: 17 givenname: Alfonso surname: Piciocchi fullname: Piciocchi, Alfonso organization: GIMEMA Foundation, Rome, Italy – sequence: 18 givenname: Claudia surname: Galimberti fullname: Galimberti, Claudia organization: Medical Department, Incyte Biosciences Italy S.R.L, Milan, Italy – sequence: 19 givenname: Alessandra surname: Iurlo fullname: Iurlo, Alessandra organization: Hematology Division, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy |
BookMark | eNp9kMlOwzAURS1UJNrCB7DzBxDwlAlWVcRQqVUr6D7yFNUoxJXtFuU_-GAcwoIVq_d0pXvfu2cGJp3tNADXGN1iXJA70VqrEoIITjDLMC3PwBSnpEgQImgCpgihLGFlji_AzPt3hDCjJJ2Cr_WxDUbqLmh3A7fO-oOWwZw05J2Crzr8UTbCa3fiwdiOt7Cye-sCfAtH1UPbwG1Ug-mMgKaD27jGTA8_TdjDar0axGXgbX8fj5gP7nq4iCm9N34wh32MN8HAnTO8vQTnDW-9vvqdc7B7etxVL8lq87ysFqtE4iItE6bzsuAi41qlWjBJJWMiww1WhJIszxHPedYIoRDLkZQ6y6lghGBMC5ZSRucAj7EylvRON_VhfK3GqB6o1j9U64FqPVKNnofRo-NfJ6Nd7WVsKrUyLmKqlTX_uL8BJBOD3w |
CitedBy_id | crossref_primary_10_1007_s11899_022_00683_3 crossref_primary_10_3390_hemato4030017 crossref_primary_10_1080_17474086_2023_2234084 crossref_primary_10_1007_s00277_023_05168_8 crossref_primary_10_1016_j_clml_2023_03_004 crossref_primary_10_1186_s13045_022_01309_0 |
ContentType | Journal Article |
Copyright | 2021 American Society of Hematology |
Copyright_xml | – notice: 2021 American Society of Hematology |
DBID | AAYXX CITATION |
DOI | 10.1182/blood-2021-146139 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Biology Anatomy & Physiology |
EISSN | 1528-0020 |
EndPage | 3603 |
ExternalDocumentID | 10_1182_blood_2021_146139 S0006497121055270 |
GroupedDBID | --- -~X .55 1CY 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6J9 AAEDW AAXUO ABOCM ABVKL ACGFO ADBBV AENEX AFOSN AHPSJ ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 IH2 K-O KQ8 L7B LSO MJL N9A OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV ZA5 0R~ 0SF AALRI AAYXX ADVLN AFETI AITUG AKRWK CITATION H13 |
ID | FETCH-LOGICAL-c1859-4e798ab6aed5eb4c3c44b61f1d2326770a7a6fbbd0470cce673b422113845343 |
IEDL.DBID | ABVKL |
ISSN | 0006-4971 |
IngestDate | Thu Sep 12 16:41:59 EDT 2024 Fri Feb 23 02:41:45 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement 1 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1859-4e798ab6aed5eb4c3c44b61f1d2326770a7a6fbbd0470cce673b422113845343 |
OpenAccessLink | https://doi.org/10.1182/blood-2021-146139 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1182_blood_2021_146139 elsevier_sciencedirect_doi_10_1182_blood_2021_146139 |
PublicationCentury | 2000 |
PublicationDate | 2021-11-23 |
PublicationDateYYYYMMDD | 2021-11-23 |
PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-23 day: 23 |
PublicationDecade | 2020 |
PublicationTitle | Blood |
PublicationYear | 2021 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
SSID | ssj0014325 |
Score | 2.4191816 |
Snippet | Background. Ponatinib is a third-generation tyrosine kinase inhibitor indicated for adults with resistant or intolerant chronic phase (CP), accelerated phase... Abstract Background. Ponatinib is a third-generation tyrosine kinase inhibitor indicated for adults with resistant or intolerant chronic phase (CP),... |
SourceID | crossref elsevier |
SourceType | Aggregation Database Publisher |
StartPage | 3603 |
Title | Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial |
URI | https://dx.doi.org/10.1182/blood-2021-146139 |
Volume | 138 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5REC0XRJdWUB6aQ8UBNdrYceLAbYlAvBa21bbiFtleR82BLNpuD_s_-MHM5IGoVC7cIksjW5mR55vxzHwAX2Mto4Li40A4pjCT0gUmVXGgPVNbS5NKy_mO4U1y_lNd3sV3S5B1vTBcVtne_c2dXt_W7Uq__Zv9h7LkHl9yp0eaJ2DxGDGK21ckoV8y9pXBya-r6-fHBBXJhsiAgmcWaB83CVn3m-pwyXUKTHDNlOH_c08vXM7ZBqy3WBEHzXE-wpKverA5qChOvl_gAdbVm3VavAerJ93Xh6zjcOvB-2H7dL4Jj3WrLddi-tk3HM2mXY8lmmqCP_z8xcqtfc7V0v7Z9DdhdOSKwwVOCxxxwr2sSotlhaNmLusf5IQuZsNrXrwgRL84pk3qSRbYDT5hYcKbeFvOSxyz5X-C8dnpODsPWkqGwJFjJ2V6fZQamxg_ib1VLnJK2UQUYkLILNE6NNokhbWTUOnQOZ_oyJIBCBGRAUQq-gzL1bTyW4ChcmFYpCa0JlbW0pfQzgvprC6ckHYbDjtF5A_NcfM6YEllXmstZ63ljda2QXWqyv-xnpwcw-tiX94mtgNrjcWIQEa7sDyf_fV7BE3mdr81vX14d_U9fQJ3leLh |
link.rule.ids | 315,783,787,27583,27938,27939,45677 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LTxsxEB4hUEsvFQ0g3p1D1UPVVdZe73rhFlZFoSQQVSnitrIdr7qHblAaDvkf_ODO7ANRqVy4WZZGtjyjmW_G8wD4FGsZFeQfB8LxCDMpXWBSFQfa82hraVJpOd4xvk6GP9X3u_huDbKuFobTKlvd3-j0Wlu3O_32Nfv3Zck1vmROTzV3wOI2YuS3bxAa0OSBbQzOb69GT58JKpLNIANynpmg_dwkZN1vssMl5ynwgGseGf4_8_TM5FxswfsWK-Kguc4HWPNVD7YHFfnJv1f4GevszTos3oM3591qM-tmuPXg7bj9Ot-Gx7rUlnMx_eIrThbzrsYSTTXDH375bOfGPsVq6fxs_oswOnLG4QrnBU444F5WpcWywknTl_UPckAXs_GINy8J0a_O6JC6kwV2jU-YmPAm3pTLEqcs-Tswvfg2zYZBO5IhcGTYiZlen6bGJsbPYm-Vi5xSNhGFmBEyo7cPjTZJYe0sVDp0zic6siQAQkQkAJGKdmG9mld-DzBULgyL1ITWxMpaWgntvJDO6sIJaffhS8eI_L65bl47LKnMa67lzLW84do-qI5V-T_Sk5NheJns4HVkH2FzOB2P8tHl9dUhvGukRwQyOoL15eLBHxNMWdqTVgz_Aur-5No |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multicenter%2C+Prospective+and+Retrospective+Observational+Cohort+Study+of+Ponatinib+in+Patients+with+CML+in+Italy%3A+Primary+Analysis+of+the+Oiti+Trial&rft.jtitle=Blood&rft.au=Breccia%2C+Massimo&rft.au=Luciano%2C+Luigia&rft.au=Annunziata%2C+Mario&rft.au=Attolico%2C+Imma&rft.date=2021-11-23&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=138&rft.issue=Supplement+1&rft.spage=3603&rft.epage=3603&rft_id=info:doi/10.1182%2Fblood-2021-146139&rft.externalDBID=n%2Fa&rft.externalDocID=10_1182_blood_2021_146139 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |